As shown in Fig. 5i, B16F10 tumors were completely eliminated in three out of five treated mice, clearly indicating that anti-PD-L1 antibody treatment improved the overall therapeutic efficacy of BNT162b2-based cancer therapy in the melanoma model. This evidence concerns the gene CD274 and melanoma.